CA
NZ
UK
AU
IND
US
The Ebola outbreak in the Democratic Republic of the Congo has escalated rapidly, with over 4,300 reported cases challenging local healthcare systems. GeoVax Labs, Inc. is stepping forward, leveraging its expertise in vaccine development against high-consequence viruses to potentially assist in combatting this unprecedented …
Abeona Therapeutics Inc. (NASDAQ: ABEO) reported a 31% quarter-over-quarter increase in net revenue for its ZEVASKYN product, reaching $11.4 million for Q2 2026. This significant growth reflects the company’s effective commercial strategy and expanding treatment network, which will likely enhance market confidence in its …
OnKure Therapeutics, Inc. (NASDAQ: OKUR), a pharmaceutical company with a marketCapitalizationof $164 million and $166.50 million in cash and equivalents, has made significant adjustments to its executive stock option program. On August 7, 2026, the company repriced its stock options for certain key employees …
The reduced loss illustrates the company’s efforts in managing expenses effectively, significant given that RVPH market capitalization stands at only $6 million. The substantial decline in share price over the past year, down 92.6% year-to-date, highlights investor caution, underscoring the urgency of Reviva’s financial …
The company anticipates that the transaction will provide net proceeds of roughly $164.0 million, which will be directed toward advancing its clinical‑stage siRNA programs.
Talphera, Inc. (NASDAQ: TLPH), operating in the pharmaceuticals sector with a marketCapitalizationof $76 million, has reported a net loss of $4.3 million for the second quarter of 2026. The company's financial results come at a key time as its NEPHRO CRRT clinical study of …
Outlook Therapeutics, Inc. (NASDAQ: OTLK) is a biotechnology company with a market capitalization of $206 million, focused on innovative therapies. The company recently reported that it has approximately $11.2 million in cash and cash equivalents as of June 30, 2026. This figure, however, remains …
Sangamo Therapeutics, Inc. (NASDAQ: SGMOQ), a genomic medicine leader specializing in groundbreaking therapeutic technologies, has announced substantial developments following its Chapter 11 filing. The company has successfully concluded asset sales that willYieldapproximately $163.55 million at closing, along with potential future milestone payments that could …
The recent financing move dovetails directly with the FDA clearance of the DeepView System for burn indication, unlocking the ability of the Dallas‑based AI firm to commence commercial sales before year‑end. By securing a $6.5 million non‑dilutive infusion, the company has lifted its cash …
The firm disclosed that its lead candidate GX‑03 will now enroll between 120 and 135 patients in the ongoing Phase 2 study of atopic dermatitis, a move designed to broaden the patient pool and increase the robustness of the trial’s statistical analysis. By expanding …
Please wait processing your request...